Second Quarter Business Results for Fiscal 2013

from the beginning

Second Quarter Business Results for Fiscal 2013

presenter :

President,
Representative Director
Terukazu Kato

2Q Business Results for Fiscal 2013, ending March 31, 2014

• 2Q Consolidated Performance for Fiscal 2013

• Key Points in 2Q Performance

• Analysis of Sales

• Factors in Increase / Decrease of Operating Profit

• Analysis of Sales Cost Ratio

• Analysis of Inventories Increase

• Financial Position

• Cash Flow Position

Addressing Strategic Issues and Progress Status

• Expanding Prescription Kampo Product Market in Japan

• Establishment of Kampo Medicine-Changes in External Environment

• Study Groups and Seminars for All Medical Specialty Fields at Designated Hospitals for Clinical Training

• MR Activities (1)

• MR Activities (2)

• Growth in Physicians Prescribing Kampo Medicine (New addition)

• Actual Unit Sales for the Last 12 Months

• Progress with Production Cost Structure Reform

• Progress with Labor Productivity (Compared with FY2011)

• Newly Introduced Production Technology (New Granulation System)

• Capital Investment Plan

• Status of Crude Drug Prices (1)

• Status of Crude Drug Prices (2)

• Status of Crude Drug Prices (3)

• Status of Crude Drug Prices (4)

• Return of Profits to Shareholders

FY2013 (Year Ending March 2014)Performance Forecasts

• FY2013 (Year Ending March 2014) Performance Forecasts

Regarding the conclusion of the sponsor agreement with the University of Oxford

Further Information

• Top 10 Kampo Products by Sales Amount

• Evidence Building for Drug Fostering Program Products(DB-RCT & Safety)

@